Literature DB >> 11440809

Bone morphogenetic protein-2, but not bone morphogenetic protein-7, promotes dendritic growth and calbindin phenotype in cultured rat striatal neurons.

E Gratacòs1, N Checa, J Alberch.   

Abstract

Bone morphogenetic proteins are members of the transforming growth factor-beta superfamily. They are widely expressed in the mammalian nervous system, where they exert trophic effects on several neuronal populations. We studied the neurotrophic activity of bone morphogenetic protein-2 and bone morphogenetic protein-7 (also called osteogenic protein-1) on cultured striatal cells, previously shown to express bone morphogenetic protein ligands and receptors. Our results indicate that only bone morphogenetic protein-2 promoted the differentiation of GABAergic neurons, especially of the calbindin-positive subpopulation, the subset of projecting striatal neurons that degenerates in Huntington's disease. Bone morphogenetic protein-2 increased the area, perimeter and degree of arborization of GABAergic neurons, promoting calbindin phenotype without altering proliferation or apoptosis. In contrast, neither bone morphogenetic protein-2 nor -7 affected striatal cholinergic interneurons. However, they both increased the number of glial fibrillary acidic protein-positive cells. Suppression of glial proliferation with 5-fluorodeoxyuridine did not abolish bone morphogenetic protein-2 effects on the differentiation of striatal neurons, ruling out an indirect mechanism through astrocytes. In conclusion, our results show that bone morphogenetic protein-2 promotes the differentiation of cultured GABAergic striatal neurons, suggesting that bone morphogenetic proteins are involved in the development of the striatum.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11440809     DOI: 10.1016/s0306-4522(01)00122-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

1.  Mesencephalic dopamine neuron number and tyrosine hydroxylase content: Genetic control and candidate genes.

Authors:  C Vadasz; J F Smiley; K Figarsky; M Saito; R Toth; B M Gyetvai; M Oros; K K Kovacs; P Mohan; R Wang
Journal:  Neuroscience       Date:  2007-07-17       Impact factor: 3.590

2.  Iba1(+)/NG2(+) macrophage-like cells expressing a variety of neuroprotective factors ameliorate ischemic damage of the brain.

Authors:  Anna Smirkin; Hiroaki Matsumoto; Hisaaki Takahashi; Akihiro Inoue; Masahiko Tagawa; Shiro Ohue; Hideaki Watanabe; Hajime Yano; Yoshiaki Kumon; Takanori Ohnishi; Junya Tanaka
Journal:  J Cereb Blood Flow Metab       Date:  2009-10-28       Impact factor: 6.200

Review 3.  Traumatized and inflamed--but resilient: glial aromatization and the avian brain.

Authors:  Kelli A Duncan; Bradley J Walters; Colin J Saldanha
Journal:  Horm Behav       Date:  2012-03-05       Impact factor: 3.492

Review 4.  The Wnt and BMP families of signaling morphogens at the vertebrate neuromuscular junction.

Authors:  Juan P Henríquez; Catherine E Krull; Nelson Osses
Journal:  Int J Mol Sci       Date:  2011-12-05       Impact factor: 5.923

5.  Growth differentiation factor 5 is a key physiological regulator of dendrite growth during development.

Authors:  Catarina Osório; Pedro J Chacón; Lilian Kisiswa; Matthew White; Sean Wyatt; Alfredo Rodríguez-Tébar; Alun M Davies
Journal:  Development       Date:  2013-10-30       Impact factor: 6.868

Review 6.  Bone morphogenetic protein signaling in vertebrate motor neurons and neuromuscular communication.

Authors:  Nelson Osses; Juan P Henríquez
Journal:  Front Cell Neurosci       Date:  2015-01-27       Impact factor: 5.505

7.  Neuron type-specific increase in lamin B1 contributes to nuclear dysfunction in Huntington's disease.

Authors:  Rafael Alcalá-Vida; Marta Garcia-Forn; Carla Castany-Pladevall; Jordi Creus-Muncunill; Yoko Ito; Enrique Blanco; Arantxa Golbano; Kilian Crespí-Vázquez; Aled Parry; Guy Slater; Shamith Samarajiwa; Sandra Peiró; Luciano Di Croce; Masashi Narita; Esther Pérez-Navarro
Journal:  EMBO Mol Med       Date:  2020-12-28       Impact factor: 14.260

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.